BioVie Inc. (BIVI): Pioneering Innovative Therapies for Neurodegenerative and Liver Diseases

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, including Long COVID, Alzheimer's disease, and Parkinson’s disease, as well as advanced liver disease. The company's approach to treating neurodegenerative diseases centers around its drug candidate bezisterim, which selectively inhibits inflammatory activation of extracellular signal-regulated kinase (ERK) and the transcription factor, Nuclear factor-kB (NFkB). This targeted inhibition helps combat neuroinflammation and insulin resistance, key drivers of Alzheimer's and Parkinson's diseases. Persistent systematic inflammation and neuroinflammation are also prominent features in patients with neurological symptoms of Long COVID, making bezisterim a potential therapeutic option for this condition as well.


In the realm of liver disease, BioVie's Orphan drug candidate BIV201, a continuous infusion of terlipressin, is being evaluated and discussed with the FDA regarding the design of Phase 3 clinical testing. BIV201 is intended to reduce further decompensation in participants with liver cirrhosis and ascites. The active agent in BIV201 is approved in the U.S. and about 40 other countries for related complications of advanced liver cirrhosis, demonstrating its potential as a valuable treatment option for patients with liver disease.


BioVie's commitment to innovation and its focus on addressing critical unmet medical needs position the company as a promising player in the healthcare industry. With a strong pipeline of drug candidates and a dedicated team of experts, BioVie is well-positioned to make a significant impact on the lives of patients suffering from neurological and neurodegenerative disorders, as well as advanced liver disease. As the company continues to advance its clinical-stage programs, investors should keep a close eye on BioVie's progress and the potential for significant value creation in the years to come.